{"id":4226,"date":"2024-04-24T18:55:32","date_gmt":"2024-04-24T10:55:32","guid":{"rendered":"https:\/\/flcube.com\/?p=4226"},"modified":"2024-11-26T13:40:11","modified_gmt":"2024-11-26T05:40:11","slug":"chinas-insulin-volume-based-procurement-tender-results-renewed-with-17-higher-contracted-value","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=4226","title":{"rendered":"China’s Insulin Volume-Based Procurement Tender Results Renewed with 17% Higher Contracted Value"},"content":{"rendered":"\n

The renewal of winning bids from the insulin volume-based procurement (VBP) tender, initially held in March 2022, has been finalized and is open for public feedback from April 24 to 26. A total of 49 insulin products from 13 manufacturers have been awarded renewed tender spots, with a total contracted value exceeding RMB 6 billion (USD 830 million), marking a 17% increase compared to the 2022 tender round. The average price reduction, when compared with the highest valid quotations, remained generally flat, especially for foreign manufacturers with originator brands, who renewed bids with a minimum price cut of only 1%. YiChang HEC\u2019s (HKG: 1558<\/a>) insulin aspart faced the steepest price cut requirement at 56%.<\/p>\n\n\n\n

Among the manufacturers, Novo Nordisk (NYSE: NVO<\/a>) led with RMB 1.7 billion (USD 230 million) in contracted values, accounting for 28.6% of the total, which is 19% less than in the 2022 tender. Gan & Lee Pharma secured contracts worth RMB 1.4 billion, a significant increase of 99% from the initial tender, claiming second place. Sanofi\u2019s contract value increased by 14% to RMB 1 billion, while Tonghua Dongbao (SHA: 600867<\/a>)\u2019s contract amount saw a 13.7% rise to RMB 820 million.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

The renewal of winning bids from the insulin volume-based procurement (VBP) tender, initially held in…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[4],"tags":[2358,859,148,860,861,441,82],"class_list":["post-4226","post","type-post","status-publish","format-standard","hentry","category-policy-regulatory","tag-hec-changjiang-pharmaceutical","tag-hkg-1558","tag-novo-nordisk","tag-nyse-nvo","tag-sha-600867","tag-tonghua-dongbao-pharmaceuticals","tag-vbp-voluem-based-procurement"],"yoast_head":"\nChina's Insulin Volume-Based Procurement Tender Results Renewed with 17% Higher Contracted Value - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The renewal of winning bids from the insulin volume-based procurement (VBP) tender, initially held in March 2022, has been finalized and is open for public feedback from April 24 to 26. A total of 49 insulin products from 13 manufacturers have been awarded renewed tender spots, with a total contracted value exceeding RMB 6 billion (USD 830 million), marking a 17% increase compared to the 2022 tender round. The average price reduction, when compared with the highest valid quotations, remained generally flat, especially for foreign manufacturers with originator brands, who renewed bids with a minimum price cut of only 1%. YiChang HEC\u2019s (HKG: 1558) insulin aspart faced the steepest price cut requirement at 56%.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=4226\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"China's Insulin Volume-Based Procurement Tender Results Renewed with 17% Higher Contracted Value\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=4226\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-24T10:55:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-26T05:40:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=4226#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=4226\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"China’s Insulin Volume-Based Procurement Tender Results Renewed with 17% Higher Contracted Value\",\"datePublished\":\"2024-04-24T10:55:32+00:00\",\"dateModified\":\"2024-11-26T05:40:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=4226\"},\"wordCount\":189,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"HEC ChangJiang Pharmaceutical\",\"HKG: 1558\",\"Novo Nordisk\",\"NYSE: NVO\",\"SHA: 600867\",\"Tonghua Dongbao Pharmaceuticals\",\"VBP (voluem-based procurement)\"],\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=4226#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=4226\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=4226\",\"name\":\"China's Insulin Volume-Based Procurement Tender Results Renewed with 17% Higher Contracted Value - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-04-24T10:55:32+00:00\",\"dateModified\":\"2024-11-26T05:40:11+00:00\",\"description\":\"The renewal of winning bids from the insulin volume-based procurement (VBP) tender, initially held in March 2022, has been finalized and is open for public feedback from April 24 to 26. A total of 49 insulin products from 13 manufacturers have been awarded renewed tender spots, with a total contracted value exceeding RMB 6 billion (USD 830 million), marking a 17% increase compared to the 2022 tender round. The average price reduction, when compared with the highest valid quotations, remained generally flat, especially for foreign manufacturers with originator brands, who renewed bids with a minimum price cut of only 1%. YiChang HEC\u2019s (HKG: 1558) insulin aspart faced the steepest price cut requirement at 56%.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=4226#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=4226\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=4226#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"China’s Insulin Volume-Based Procurement Tender Results Renewed with 17% Higher Contracted Value\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"China's Insulin Volume-Based Procurement Tender Results Renewed with 17% Higher Contracted Value - Insight, China's Pharmaceutical Industry","description":"The renewal of winning bids from the insulin volume-based procurement (VBP) tender, initially held in March 2022, has been finalized and is open for public feedback from April 24 to 26. A total of 49 insulin products from 13 manufacturers have been awarded renewed tender spots, with a total contracted value exceeding RMB 6 billion (USD 830 million), marking a 17% increase compared to the 2022 tender round. The average price reduction, when compared with the highest valid quotations, remained generally flat, especially for foreign manufacturers with originator brands, who renewed bids with a minimum price cut of only 1%. YiChang HEC\u2019s (HKG: 1558) insulin aspart faced the steepest price cut requirement at 56%.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=4226","og_locale":"en_US","og_type":"article","og_title":"China's Insulin Volume-Based Procurement Tender Results Renewed with 17% Higher Contracted Value","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=4226","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-04-24T10:55:32+00:00","article_modified_time":"2024-11-26T05:40:11+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=4226#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=4226"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"China’s Insulin Volume-Based Procurement Tender Results Renewed with 17% Higher Contracted Value","datePublished":"2024-04-24T10:55:32+00:00","dateModified":"2024-11-26T05:40:11+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=4226"},"wordCount":189,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["HEC ChangJiang Pharmaceutical","HKG: 1558","Novo Nordisk","NYSE: NVO","SHA: 600867","Tonghua Dongbao Pharmaceuticals","VBP (voluem-based procurement)"],"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=4226#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=4226","url":"https:\/\/flcube.com\/?p=4226","name":"China's Insulin Volume-Based Procurement Tender Results Renewed with 17% Higher Contracted Value - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-04-24T10:55:32+00:00","dateModified":"2024-11-26T05:40:11+00:00","description":"The renewal of winning bids from the insulin volume-based procurement (VBP) tender, initially held in March 2022, has been finalized and is open for public feedback from April 24 to 26. A total of 49 insulin products from 13 manufacturers have been awarded renewed tender spots, with a total contracted value exceeding RMB 6 billion (USD 830 million), marking a 17% increase compared to the 2022 tender round. The average price reduction, when compared with the highest valid quotations, remained generally flat, especially for foreign manufacturers with originator brands, who renewed bids with a minimum price cut of only 1%. YiChang HEC\u2019s (HKG: 1558) insulin aspart faced the steepest price cut requirement at 56%.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=4226#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=4226"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=4226#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"China’s Insulin Volume-Based Procurement Tender Results Renewed with 17% Higher Contracted Value"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/4226","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4226"}],"version-history":[{"count":3,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/4226\/revisions"}],"predecessor-version":[{"id":15005,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/4226\/revisions\/15005"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4226"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4226"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4226"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}